GV returned for a series C round that helped the precision cancer medicine developer increase its overall funding to over $180m.
FogPharma, a US-based cancer precision medicine developer received $107m on Wednesday in a series C round featuring GV, a corporate venturing subsidiary of internet and technology group Alphabet.
The round was led by life sciences investment firm VenBio Partners and included 6 Dimensions Capital, an investment firm co-founded by pharmaceutical firm WuXi AppTec.
Cormorant Asset Management, Farallon Capital Management, Invus, HBM Healthcare Investments, Casdin Capital, PagsGroup, Deerfield Management, Blue Pool Capital and funds and accounts advised by T Rowe Price…